Pharmacokinetics of rifabutin in Japanese HIV-infected patients with or without antiretroviral therapy.

Pharmacokinetics of rifabutin in Japanese HIV-infected patients with or without antiretroviral therapy.

OBJECTIVE: Based on drug-drug interaction, dose reduction of rifabutin is recommended when co-administered with HIV protease inhibitors for human immunodeficiency virus (HIV)-associated mycobacterial infection. The aim of this study was to compare the pharmacokinetics of rifabutin administered at 30...

Full description

Bibliographic Details
Main Authors:	Junko Tanuma, Kazumi Sano, Katsuji Teruya, Koji Watanabe, Takahiro Aoki, Haruhito Honda, Hirohisa Yazaki, Kunihisa Tsukada, Hiroyuki Gatanaga, Yoshimi Kikuchi, Shinichi Oka
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3734254?pdf=render

Similar Items

Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.
by: Takeshi Nishijima, et al.
Published: (2012-01-01)

Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.
by: Takeshi Nishijima, et al.
Published: (2011-01-01)

High Mortality of Disseminated Non-Tuberculous Mycobacterial Infection in HIV-Infected Patients in the Antiretroviral Therapy Era.
by: Tetsuro Kobayashi, et al.
Published: (2016-01-01)

Preemptive therapy prevents cytomegalovirus end-organ disease in treatment-naïve patients with advanced HIV-1 infection in the HAART era.
by: Daisuke Mizushima, et al.
Published: (2013-01-01)

Incidence and Risk Factors for Incident Syphilis among HIV-1-Infected Men Who Have Sex with Men in a Large Urban HIV Clinic in Tokyo, 2008-2015.
by: Takeshi Nishijima, et al.
Published: (2016-01-01)

Anal human papillomavirus infection and its relationship with abnormal anal cytology among MSM with or without HIV infection in Japan
by: Daisuke Shiojiri, et al.
Published: (2021-09-01)

Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
by: Haruka Uemura, et al.
Published: (2017-01-01)

Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
by: Takeshi Nishijima, et al.
Published: (2013-01-01)

Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.
by: Nguyen Thi Ngoc Lan, et al.
Published: (2014-01-01)

A pharmacokinetic study of rifabutin and its interaction with antiretrovirals in African patients with TB-HIV co-infection.
by: Naiker, Suhashni.
Published: (2013)

Cerebral Syphilitic Gumma within 5 Months of Syphilis in HIV-Infected Patient
by: Motoyuki Tsuboi, et al.
Published: (2016-10-01)

A 21-Day of Adjunctive Corticosteroid Use May Not Be Necessary for HIV-1-Infected Pneumocystis Pneumonia with Moderate and Severe Disease.
by: Satoshi Shibata, et al.
Published: (2015-01-01)

Pharmacokinetics, Biodistribution and Toxicity Studies for Nanocarrier of Antitubercular Agent- Rifabutin
by: Swapnil Patil, et al.
Published: (2020-12-01)

Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous stem cell transplantation and highly active antiretroviral therapy
by: Hiroki Goto, et al.
Published: (2011-03-01)

Routine Eye Screening by an Ophthalmologist Is Clinically Useful for HIV-1-Infected Patients with CD4 Count Less than 200 /μL.
by: Takeshi Nishijima, et al.
Published: (2015-01-01)

Case report: new development of fibrosing interstitial lung disease triggered by HIV-related pneumocystis pneumonia
by: Tetsuya Suzuki, et al.
Published: (2019-03-01)

Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?
by: Yohei Hamada, et al.
Published: (2013-01-01)

WHO antiretroviral therapy guidelines 2010 and impact of tenofovir on chronic kidney disease in Vietnamese HIV-infected patients.
by: Daisuke Mizushima, et al.
Published: (2013-01-01)

Combination of Clindamycin and Azithromycin as Alternative Treatment for Toxoplasma gondii Encephalitis
by: Daisuke Shiojiri, et al.
Published: (2019-04-01)

A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects.
by: M Ghannad, et al.
Published: (2019-01-01)

Treatment outcomes of rifabutin-containing regimens for rifabutin-sensitive multidrug-resistant pulmonary tuberculosis
by: Hyun Lee, et al.
Published: (2017-12-01)

Enteral entrance of Mycobacterium avium in patients with disseminated mycobacterial disease
by: Kenji Hibiya, et al.
Published: (2013-01-01)

Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus
by: Naokatsu Ando, et al.
Published: (2021-09-01)

Acute hepatitis C in HIV-1 infected Japanese Cohort: single center retrospective cohort study.
by: Masahiro Ishikane, et al.
Published: (2014-01-01)

Comments regarding use of rifabutin for eradication
by: David Y. Graham
Published: (2021-10-01)

Emergence of CXCR4-tropic HIV-1 variants followed by rapid disease progression in hemophiliac slow progressors.
by: Tsunefusa Hayashida, et al.
Published: (2017-01-01)

Safety of Rifabutin in patients with rifampicin-induced thrombocytopenia
by: Trina Sarkar, et al.
Published: (2020-01-01)

Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?
by: S. Tiberi, et al.
Published: (2017-12-01)

HIV-1 infection, but not syphilis or HBV infection, is a strong risk factor for anorectal condyloma in Asian population: A prospective colonoscopy screening study
by: Takeshi Nishijima, et al.
Published: (2015-08-01)

Factors associated with esophageal candidiasis and its endoscopic severity in the era of antiretroviral therapy.
by: So Nishimura, et al.
Published: (2013-01-01)

Spherical amorphous nanoparticles loading with antituberculosis substance rifabutin
by: A. P. Kaplun, et al.
Published: (2010-04-01)

Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?
by: Carolina Arana Stanis Schmaltz, et al.
Published: (2019-02-01)

Ex Vivo Human Placental Transfer of Rifampin and Rifabutin
by: Kevin P. Magee, et al.
Published: (1996-01-01)

Amebiasis in HIV-1-infected Japanese men: clinical features and response to therapy.
by: Koji Watanabe, et al.
Published: (2011-09-01)

High prevalence and incidence of rectal Chlamydia infection among men who have sex with men in Japan.
by: Daisuke Mizushima, et al.
Published: (2019-01-01)

Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients
by: Seni Kouanda, et al.
Published: (2020-06-01)

Rifabutin-Cobicistat Drug Interaction Resulting in Severe Bilateral Panuveitis
by: Christopher B. Toomey, et al.
Published: (2020-04-01)

The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks.
by: Frederick A Sirgel, et al.
Published: (2013-01-01)

Rifabutin: A Repurposing Candidate for Mycobacterium abscessus Lung Disease
by: Thomas Dick, et al.
Published: (2020-02-01)

Predictive clinical factors in the diagnosis of gastrointestinal Kaposi's sarcoma and its endoscopic severity.
by: Naoyoshi Nagata, et al.
Published: (2012-01-01)